ଡେଲାମାନିଡ

ଡେଲାମାନିଡ
Clinical data
Trade names	Deltyba
Synonyms	OPC-67683
AHFS/Drugs.com	International Drug Names
Routes of; administration	by mouth (film-coated tablets)
ATC code	J04AK06 (WHO) ;
Legal status
Legal status	℞ (Prescription only);
Pharmacokinetic data
Protein binding	≥99.5%
Metabolism	in plasma by albumin, in liver; by CYP3A4 (to a lesser extent)
Elimination half-life	30–38 hours
Excretion	not excreted in urine
Identifiers
	IUPAC name (2R)-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole;
CAS Number	681492-22-8;
PubChem CID	6480466;
ChemSpider	4981055;
UNII	8OOT6M1PC7;
KEGG	D09785;
ChEMBL	CHEMBL218650;
ECHA InfoCard	100.348.783
Chemical and physical data
Formula	C25H25F3N4O6
Molar mass	534.48 g/mol
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)Oc5ccc(OC4CCN(c3ccc(OC[C@@]2(Oc1nc(cn1C2)[N+]([O-])=O)C)cc3)CC4)cc5;
	InChI InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1; Key:XDAOLTSRNUSPPH-XMMPIXPASA-N;

ଡେଲାମାନିଡ (ଇଂରାଜୀ ଭାଷାରେDelamanid, ବିକ୍ରୟ ନାମ ଡେଲଟିବା/Deltyba) ଏକ ଔଷଧ ଯାହା ଯକ୍ଷ୍ମା ରୋଗର ଚିକିତ୍ସା ନିମନ୍ତେ ଦିଆଯାଏ । ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ବ‌ହୁ ଔଷଧ ପ୍ରତିରୋଧୀ ଯକ୍ଷ୍ମା (multidrug-resistant tuberculosis) ରୋଗରେ ଅନ୍ୟାନ୍ୟ ଯକ୍ଷ୍ମାବିରୋଧୀ ଔଷଧମାନଙ୍କ (antituberculosis medication) ସ‌ହିତ ବ୍ୟବ‌ହୃତ ହୁଏ । ଏହି ଔଷଧ ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ଡେଲାମାନିଡର ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବଥା, ମୁଣ୍ଡବୁଲା ଓ ଅଇ ଇତ୍ୟାଦି ଲକ୍ଷଣ ଦେଖାଯାଏ ।^[୩] ଏହାର ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଲମ୍ବା କ୍ୟୁଟି (QT prolongation) ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ଏହାର ପ୍ରଭାବ ବିଷୟରେ ସନ ୨୦୧୬ ସୁଦ୍ଧା ଅନୁଶୀଳନ ହୋଇନାହିଁ । ^[୪] ମାଇକୋଲିକ ଏସିଡ (mycolic acid) ପ୍ରସ୍ତୁତିକୁ ଡେଲାମାନିଡ ଅବରୋଧ କରି ଜୀବାଣୁ କୋଷାବରଣ (cell wall) ତିଆରିରେ ବାଧା ସୃଷ୍ଟି କରେ ।^[୫]

ଡେଲାମାନିଡ ସନ ୨୦୧୪ରେ ୟୁରୋପ, ଜାପାନ ଓ ଦକ୍ଷିଣ କୋରିଆରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ସ୍ୱୀକୃତିପ୍ରାପ୍ତ ହେଲା ।^[୬] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ (World Health Organization's List of Essential Medicines) ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ (health system) ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୭] ସନ ୨୦୧୬ରେ ସ୍ଟପ ଟିବି ପାର୍ଟନରସିପ (Stop TB Partnership) ସଂସ୍ଥା ଶହେଟି ଦେଶ ସ‌ହିତ ଏକ ଚୁକ୍ତି ସ୍ୱାକ୍ଷର କରିଥିଲେ ଯେଉଁଥିରେ ୬ ମାସ ନିମନ୍ତେ ଏହା ମୂଲ୍ୟ ୧୭୦୦ ଆମେରିକୀୟ ଡଲାର ରହିବ ବୋଲି ସ୍ୱିକୃତ ହୋଇଥିଲା ।^[୮]

ଆଧାର

↑ "Deltyba (delamanid): Summary of Product Characteristics. 5.2. Pharmacokinetic Properties" (PDF). Otsuka Novel Products GmbH. p. 10. Archived from the original (PDF) on 17 August 2016. Retrieved 9 July 2016.
↑ ^୨.୦ ^୨.୧ The selection and use of essential medicines: Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children) (PDF). WHO. 2015. pp. 29–31. ISBN 9789240694941.
↑ Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions (in ଇଂରାଜୀ). Elsevier. 2016. p. 284. ISBN 9780444638892.
↑ Cohen, Jonathan; Powderly, William G.; Opal, Steven M. (2016). Infectious Diseases (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 284. ISBN 9780702063381.
↑ Blair, HA; Scott, LJ (January 2015). "Delamanid: a review of its use in patients with multidrug-resistant tuberculosis". Drugs. 75 (1): 91–100. PMID 25404020.
↑ Fischer, Janos (2016). Successful Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 139. ISBN 9783527341153.
↑ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
↑ "Stop TB Partnership | "Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships". www.stoptb.org (in ଇଂରାଜୀ). Archived from the original on 16 January 2017. Retrieved 15 January 2017.

[1] "Deltyba (delamanid): Summary of Product Characteristics. 5.2. Pharmacokinetic Properties" (PDF). Otsuka Novel Products GmbH. p. 10. Archived from the original (PDF) on 17 August 2016. Retrieved 9 July 2016.

[WHO2015Use-2] ୨.୦ ^୨.୧ The selection and use of essential medicines: Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children) (PDF). WHO. 2015. pp. 29–31. ISBN 9789240694941.

[World2016-3] Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions (in ଇଂରାଜୀ). Elsevier. 2016. p. 284. ISBN 9780444638892.

[4] Cohen, Jonathan; Powderly, William G.; Opal, Steven M. (2016). Infectious Diseases (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 284. ISBN 9780702063381.

[5] Blair, HA; Scott, LJ (January 2015). "Delamanid: a review of its use in patients with multidrug-resistant tuberculosis". Drugs. 75 (1): 91–100. PMID 25404020.

[6] Fischer, Janos (2016). Successful Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 139. ISBN 9783527341153.

[WHO19th-7] "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.

[TB2016-8] "Stop TB Partnership | "Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships". www.stoptb.org (in ଇଂରାଜୀ). Archived from the original on 16 January 2017. Retrieved 15 January 2017.

[୨]

[୧]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]